(HealthDay)—Recipients of the herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, develop robust immune responses, according to a study published in the June 1 issue of The Journal of Infectious Diseases. Anthony L. Cunningham, M.D., from the University of Sydney, and colleagues presented immunogenicity results from two trials involving patients aged 50 […]

Continue reading »